These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30478106)

  • 21. Three-Year Clinical Outcomes Associated With Warfarin vs. Direct Oral Anticoagulant Use Among Japanese Patients With Atrial Fibrillation　- Findings From the SAKURA AF Registry.
    Okumura Y; Yokoyama K; Matsumoto N; Tachibana E; Kuronuma K; Oiwa K; Matsumoto M; Kojima T; Hanada S; Nomoto K; Arima K; Takahashi F; Kotani T; Ikeya Y; Fukushima S; Itou S; Kondo K; Chiku M; Ohno Y; Onikura M; Hirayama A;
    Circ J; 2018 Sep; 82(10):2500-2509. PubMed ID: 30078823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
    Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
    J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protocol for a multicentre and prospective follow-up cohort study of early detection of atrial fibrillation, silent stroke and cognitive impairment in high-risk primary care patients: the PREFA-TE study.
    Hernández-Pinilla A; Clua-Espuny JL; Satué-Gracia EM; Pallejà-Millán M; Martín-Luján FM;
    BMJ Open; 2024 Feb; 14(2):e080736. PubMed ID: 38373864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bleeding Risk of Add-On Anti-Platelet Agents to Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation (From 2216 Patients in the DIRECT Registry).
    Sotomi Y; Hirata A; Amiya R; Kobayashi T; Hirayama A; Sakata Y; Higuchi Y
    Am J Cardiol; 2019 Apr; 123(8):1293-1300. PubMed ID: 30717887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis.
    Deitelzweig S; Farmer C; Luo X; Li X; Vo L; Mardekian J; Fahrbach K; Ashaye A
    Curr Med Res Opin; 2018 Mar; 34(3):487-498. PubMed ID: 29188721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term vitamin K antagonists treatment patterns of Non-Valvular Atrial Fibrillation (NVAF): a population-based cohort study.
    Renoux C; Coulombe J; Suissa S
    BMC Cardiovasc Disord; 2016 May; 16():84. PubMed ID: 27160254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
    Andersson NW; Svanström H; Lund M; Pasternak B; Melbye M
    Int J Cardiol; 2018 Oct; 268():113-119. PubMed ID: 29934230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial.
    Åsberg S; Hijazi Z; Norrving B; Terént A; Öhagen P; Oldgren J
    Trials; 2017 Dec; 18(1):581. PubMed ID: 29197413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment and persistence with oral anticoagulants among newly diagnosed patients with non-valvular atrial fibrillation: a retrospective observational study in a US commercially insured and Medicare Advantage population.
    Willey V; Franchino-Elder J; Fu AC; Wang C; Sander S; Tan H; Kraft E; Jain R
    BMJ Open; 2018 Jun; 8(6):e020676. PubMed ID: 29961012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention.
    Hirano T; Kaneko H; Mishina S; Wang F; Morita S
    J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2102-2110. PubMed ID: 28532651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation.
    Hernandez I; Zhang Y; Saba S
    Am J Cardiol; 2018 Jul; 122(1):69-75. PubMed ID: 29681367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct oral anticoagulants use in elderly patients with non valvular atrial fibrillation: state of evidence.
    Benedetti G; Neccia M; Agati L
    Minerva Cardioangiol; 2018 Jun; 66(3):301-313. PubMed ID: 29125269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-valvular atrial fibrillation patients with low CHADS2 scores benefit from warfarin therapy according to propensity score matching subanalysis using the J-RHYTHM Registry.
    Chishaki A; Kumagai N; Takahashi N; Saikawa T; Inoue H; Okumura K; Atarashi H; Yamashita T; Origasa H; Sakurai M; Kawamura Y; Kubota I; Matsumoto K; Kaneko Y; Ogawa S; Aizawa Y; Chinushi M; Kodama I; Watanabe E; Koretsune Y; Okuyama Y; Shimizu A; Igawa O; Bando S; Fukatani M;
    Thromb Res; 2015 Aug; 136(2):267-73. PubMed ID: 26092429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kidney function monitoring and nonvitamin K oral anticoagulant dosage in atrial fibrillation.
    Andreu Cayuelas JM; Caro Martínez C; Flores Blanco PJ; Elvira Ruiz G; Albendin Iglesias H; Cerezo Manchado JJ; Bailen Lorenzo JL; Januzzi JL; García Alberola A; Manzano-Fernández S
    Eur J Clin Invest; 2018 Jun; 48(6):e12907. PubMed ID: 29423910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
    Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
    BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: focus on real life studies.
    Masotti L; Grifoni E; Dei A; Vannucchi V; Moroni F; Panigada G; Spolveri S; Landini G
    J Thromb Thrombolysis; 2019 Feb; 47(2):292-300. PubMed ID: 30470967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
    Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
    Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II).
    Steinberg BA; Shrader P; Pieper K; Thomas L; Allen LA; Ansell J; Chan PS; Ezekowitz MD; Fonarow GC; Freeman JV; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli GV; Reiffel JA; Singer DE; Peterson ED; Piccini JP;
    J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29453305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.